Margaret McLoughlin
Director/Board Member chez QUINCE THERAPEUTICS, INC.
Fortune : 8 480 $ au 31/03/2024
Profil
Margaret A.
McLoughlin is an Independent Director at Quince Therapeutics, Inc. and a Director at Herophilus, Inc. She was previously an Executive Director-World Wide Business Development at Pfizer Inc. from 2014 to 2019.
She also held positions as an Associate Director at Yale University, and as a Director at BioAtla, Inc., 4D Molecular Therapeutics, Inc., and Adapsyn Bioscience, Inc. McLoughlin received her undergraduate degree from the University of California, Irvine and her doctorate from the University of California, Santa Barbara.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 08/08/2023 | 8 000 ( 0,02% ) | 8 480 $ | 31/03/2024 |
Postes actifs de Margaret McLoughlin
| Sociétés | Poste | Début |
|---|---|---|
| QUINCE THERAPEUTICS, INC. | Director/Board Member | 01/12/2015 |
Herophilus, Inc.
 Herophilus, Inc. Packaged SoftwareTechnology Services Herophilus, Inc. operates as neurotherapeutics company. It employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. The firm combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. The company was founded by Frederic J. Kerrest, Sean Escola and Saul Kato and is headquartered in San Francisco, CA. | Director/Board Member | - |
Anciens postes connus de Margaret McLoughlin
| Sociétés | Poste | Fin |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/05/2019 |
| 4D MOLECULAR THERAPEUTICS, INC. | Director/Board Member | 20/03/2019 |
| Yale University | Corporate Officer/Principal | - |
| BIOATLA, INC. | Director/Board Member | - |
Adapsyn Bioscience, Inc.
 Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada. | Director/Board Member | - |
Formation de Margaret McLoughlin
| University of California, Irvine | Undergraduate Degree |
| University of California, Santa Barbara | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| PFIZER, INC. | Health Technology |
| BIOATLA, INC. | Health Technology |
| 4D MOLECULAR THERAPEUTICS, INC. | Health Technology |
| QUINCE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Adapsyn Bioscience, Inc.
Adapsyn Bioscience, Inc. BiotechnologyHealth Technology Adapsyn Bioscience, Inc. operates as a biotechnology company focussed on the discovery and development of novel medicines. The company was founded by Nathan Magarvey and is headquartered in Hamilton, Canada. | Health Technology |
Herophilus, Inc.
Herophilus, Inc. Packaged SoftwareTechnology Services Herophilus, Inc. operates as neurotherapeutics company. It employs phenotypic screening to discover novel drugs for complex neurological and psychiatric diseases such as epilepsy, autism, and schizophrenia, disorders for which current discovery techniques have proved least successful. The firm combines cerebral organoid science, systems neuroscience, robotic automation, and advanced data analytics to discover characterizations of disease never before achievable. The company was founded by Frederic J. Kerrest, Sean Escola and Saul Kato and is headquartered in San Francisco, CA. | Technology Services |
